Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle
Search
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
Facts About IPF
IPF is a debilitating and fatal lung disease.
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Results for Jardiance EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
Sites Around the World
Sites Around the World
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
Boehringer Ingelheim reports a strong performance in 2022.
Is artificial intelligence the future of farming?
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
BTD for GlyT1 in Schizophrenia
Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
GastroGard the first imported equine drug in China
GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
We nurture innovative ideas
At Boehringer Ingelheim, we know to really make a difference we need to innovate. That’s why we embrace and invest in innovation every single day.
History video
Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Podcast: Journeys through pulmonary fibrosis
As we speak to the courageous pulmonary fibrosis community, we hear heart-warming stories of determination, resilience and spirit.
Boehringer Ingelheim strong growth pipeline acceleration 2023
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline